Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals — Investor Presentation (March 2023)

39 slides from Zynerba Pharmaceuticals's investor presentation, Mar 28, 2023

  1. Slide 1: Next-Generation Transdermal Cannabinoid Therapeutics

    © 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. NASDAQ ZYNE Advancing Science. Improving Connections. Next - Generation Transdermal Cannabinoid Therapeutics March 2023

  2. Slide 2: Forward-Looking Statements

    Forward - Looking Statements The statements in this presentation may include forward - looking statements within the meaning of the private securities litigati on reform act of 1995. These statements, among other things relate to the future operations, opportunities, or financial performance of Zy n

  3. Slide 3: A different and exciting approach to Cannabidiol

    A different and exciting approach to Cannabidiol

  4. Slide 4: An Orphan-Focused Neuropsychiatric, Biopharmaceutical Company

    An Orphan - Focused Neuropsychiatric, Biopharmaceutical Company Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 4 Permeation - enhanced Patent - protected through 2040 Pharmaceutically manufactured; THC free FIRST AND ONLY TRANSDERMAL CANNABIDIOL GEL One Phase 3 clinical program

  5. Slide 5: Benefits of Our Approach to Cannabidiol

    Benefits of Our Approach to Cannabidiol Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 5 FDA regulated Consistency of production Purity of ingredients No THC – not a scheduled drug by U.S. DEA Scalable production process PHARMACEUTICAL MANUFACTURING PHARMACEUTICAL DISPENSARY Eas

  6. Slide 6: Transdermal Administration Achieved Plasma Concentrations Overlapping Oral Cannabidiol

    • Cannabidiol pre - dose concentrations in adults with epilepsy receiving either 195 mg/day or 390 mg/day of Zygel ranged from 0.72 ng/mL to 77.50 ng/mL • Cannabidiol pre - dose concentrations peaked at 235 ng/mL in adults who received Zygel in doses ranging from 390 mg/day to 780 mg/day in the open

  7. Slide 7: Clinical Development Programs

    Clinical Development Programs Fragile X Syndrome FXS 22q Deletion Syndrome 22q

  8. Slide 8: Overlap of Symptoms Across Conditions

    Overlap of Symptoms Across Conditions Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 8 Anxiety Seeks Isolation Social Avoidance Lack of Interaction Attention Deficits Irritability FXS 22q March 2023

  9. Slide 9: Focused Clinical Pipeline

    Fragile X Syndrome (FXS) Focused Clinical Pipeline Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 9 Preclinical Phase 1 Phase 2 Pivotal Market 22q Deletion Syndrome (22q) Regulatory Filing U.S. Orphan Drug and Fast Track designations; EU Orphan Drug designation U.S. Orphan Drug

  10. Slide 10: Well-Tolerated Safety Profile

    • Zygel safety database across all clinical studies includes data from over 900 volunteers and patients • Majority of treatment - emergent AEs (TEAEs) were mild or moderate • Most common Zygel - related TEAEs were application site events, the majority of which were mild and transient • No clinically

  11. Slide 11: Fragile X Syndrome

    Fragile X Syndrome

  12. Slide 12: What is Fragile X Syndrome (FXS)?

    ~78K U.S. PATIENTS What is Fragile X Syndrome (FXS)? Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 12 • Leading known cause of inherited intellectual disability and autism spectrum disorder • Mutation of the FMR1 gene causes endocannabinoid system (ECS) dysregulation • Easily i

  13. Slide 13: Poised for Success in FXS

    Poised for Success in FXS Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 13 Largest clinical trial ever conducted in children with FXS Extensive safety database Patients on drug for up to five years Statistically significant outcomes in children with complete methylation Lessons

  14. Slide 14: Role of FMR1 Methylation in FXS

    Role of FMR1 Methylation in FXS Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 14 • FMR1 gene codes for production of FMRP* which is vital to synapse development • Methylation of the FMR1 gene plays a role in determining gene function • When methylation of the FMR1 gene silences

  15. Slide 15: CONNECT-FX Key Learning: Complete Methylation Results

    CONNECT - FX Trial Key Learning: Results with complete methylation of FMR1 gene Consistent Improvements Observed with Zygel vs. Placebo in Patients with Complete Methylation Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 15 PRIMARY ENDPOINT CAREGIVER REPORTED BEHAVIOR CHANGE CLI

  16. Slide 16: Sustained Improvement in Patients With Complete Methylation

    Sustained Improvement in Patients With Complete Methylation of FMR1 a a. Patients matching primary efficacy population in RECONNECT. b. ZYN2 - CL - 016 (CONNECT - FX). c. Least square mean ± SE; reduction equals improvement. -6 -5 -4 -3 -2 -1 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Change from ba

  17. Slide 17: Clinically Meaningful Improvement Achieved and Maintained

    Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 17 Clinically Meaningful Improvement a Achieved and Maintained in Patients with Complete Methylation b 0 10 20 30 40 50 60 70 80 90 100 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Cumulative Percentage of Patients Month Zygel (n=47) Pl

  18. Slide 18: CONNECT-FX Data Published in Journal of Neurodevelopmental Disorders

    CONNECT - FX Data Published in the Journal of Neurodevelopmental Disorders Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 18 • “…ZYN002 was well tolerated in patients with FXS and demonstrated evidence of efficacy with a favorable benefit risk relationship in patients with ≥ 90%

  19. Slide 19: Role of Endocannabinoid System and Cannabidiol Therapy in FXS

    Role of Endocannabinoid System and Cannabidiol Therapy in FXS Published in the Journal of Neurodevelopmental Disorders Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 19 • “…Multiple lines of evidence suggest a central role for the endocannabinoid system (ECS) in the neuronal dev

  20. Slide 20: Design Optimized from CONNECT-FX Trial

    Design Optimized from CONNECT - FX Trial Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 20 More patient and family friendly Extending trial to 18 - weeks Increased dosing option for individuals >50 kg Successful completion of Phase 3 pivotal trial expected to satisfy requirement

  21. Slide 21: Confirmatory Pivotal Trial Design

    Confirmatory Pivotal Trial Design Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 21 Double - Blind, Placebo - Controlled Study: Initiated 18 weeks 3 to 22 years old Moderate - to - Severe FXS Zygel (n~100; 80*) 250 mg daily (≤30kg) 500 mg daily (>30kg) 750 mg daily (>50kg) (weig

  22. Slide 22: Trial Objectives

    Trial Objectives Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 22 Change from baseline to end of treatment in ABC - C FXS Social Avoidance subscale in patients who have complete (100%) methylation of their FMR1 gene • Change from baseline to end of treatment in: • ABC - C FXS I

  23. Slide 23: Next Steps in FXS

    Next Steps in FXS Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 23 Continued RECONNECT pivotal trial enrollment Topline results expected in 1H 2024 March 2023

  24. Slide 24: 22q11.2 Deletion Syndrome (22q)

    22q11.2 Deletion Syndrome (22q) Image courtesy Positive Exposure © 2016 Positive Exposure. All rights reserved. www.PositiveExposure.org . Eliza, living with 22q11.2 deletion syndrome

  25. Slide 25: What is 22q11.2 Deletion Syndrome (22q)?

    What is 22q11.2 Deletion Syndrome (22q)? Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 25 • Rare disorder and second most common genetic disorder, behind Down s yndrome • Midline condition with abnormalities affecting palate, face, heart and other organs; surgically corrected i

  26. Slide 26: Rationale for Zygel in 22q

    U.S. & EU ORPHAN DRUG DESIGNATION GRANTED FOR TREATMENT OF 22q Rationale for Zygel in 22q Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 26 • Overlapping symptoms with FXS and ASD • Associated with increased anxiety, irritability, social withdrawal and social interaction problem

  27. Slide 27: INSPIRE Phase 2 Trial Design

    INSPIRE Phase 2 Trial Design Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 27 Period 1: Completed 14 weeks 4 to 15 years old With 22q11.2 Deletion Syndrome Zygel (n = 20) 250 mg daily (≤35kg) 500 mg daily (>35kg) (weight - based dose) Period 2: Completed 24 weeks Efficacy asses

  28. Slide 28: INSPIRE Trial Efficacy and Safety Summary

    • Statistically significant improvements at 14 weeks and 38 weeks of treatment compared to baseline for multiple efficacy assessments: • The total score and all five subscales of the Anxiety, Depression and Mood Scale (ADAMS) • All five subscales of the Aberrant Behavior Checklist – Community (ABC -

  29. Slide 29: Significant Improvement in Anxiety as Measured by PARS-R

    29 Efficacy: Significant Improvement in Anxiety as Measured by the PARS - R 14.7 8.5 0 2 4 6 8 10 12 14 16 PARS - R score 40.6% ( P =.0005) Baseline (n=15) Week 14 (n=15) 15.3 7.4 0 2 4 6 8 10 12 14 16 PARS - R score 49.4% ( P =.0001) Baseline (n=11) Week 38 (n=11) The efficacy analysis for Period 1

  30. Slide 30: Significant Improvements in ADAMS Total and Subscale Scores

    30 Efficacy: Significant Improvements in ADAMS Total and Subscale Scores Mean Scores and Percentage Improvement Period 1 14 weeks 36.1 10.4 7.6 8.7 3.0 7.6 17.7 5.1 3.4 4.3 1.1 4.4 0 5 10 15 20 25 30 35 40 Baseline (n=16) Week 14 (n=16) ADAMS total and subscale scores 45.3% ( P =.0005) 43.6% ( P= .0

  31. Slide 31: Significant Improvements in All ABC-C Subscale Scores

    31 Efficacy: Significant Improvements in All ABC - C Subscale Scores 18.4 4.2 3.9 14.4 18.1 10.0 2.4 1.6 7.9 10.4 0 2 4 6 8 10 12 14 16 18 20 Baseline (n=16) Week 14 (n=16) ABC - C subscale score 36.3% ( P =.0055) 18.3% ( P= .0166) 52.1% ( P= .0155) 16.5% ( P= .0091) 27.6% ( P= .011) Irritability In

  32. Slide 32: Next Steps in 22q

    Next Steps in 22q Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 32 Ongoing discussions with FDA regarding regulatory pathway (initial meeting Q4 2022) Finalize trial design with FDA in 2023; Initiate Phase 3 program after RECONNECT topline results March 2023

  33. Slide 33: Positioned for Success

    Positioned for Success

  34. Slide 34: Leadership

    Leadership Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 34 Armando Anido Chairman of the Board and CEO Terri B. Sebree President Jim Fickenscher CFO and VP, Corporate Development Paul Kirsch VP, Regulatory Affairs and Quality Assurance Joe Apostolico VP, Human Resources Terry

  35. Slide 35: Financial Strength

    Financial Strength Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 35 CASH AND CASH EQUIVALENTS $50.6M as of December 31, 2022; expected to be sufficient to fund operations and capital requirements to mid - year 2024 BALANCE SHEET CLEAN No debt, 53.4M shares outstanding (as of Ma

  36. Slide 36: A Year of Clinical Progress Ahead

    A Year of Clinical Progress Ahead Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 36 Fragile X Syndrome (FXS) 22q Deletion Syndrome (22q) U.S. Orphan Drug and Fast Track designations; EU Orphan Drug designation U.S. and EU Orphan Drug designations Pivotal trial results expected i

  37. Slide 37: Zynerba Vision for Future Growth

    • Leader in transdermal cannabidiol delivery • Late - stage clinical company with two orphan CNS programs in areas of high unmet need • Launch Zygel in FXS via strategic partners in EU and other Territories • Launch Zygel into additional multi - billion $ market of 22q • Optimize Zygel growth with a

  38. Slide 38: A different and exciting approach to Cannabidiol

    A different and exciting approach to Cannabidiol

  39. Slide 39: Thank you!

    © 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. NASDAQ ZYNE Thank you!

Zynerba Pharmaceuticals — Investor Presentation (March 2023) on 6ix